Cognizant To Acquire Belcan For About $1.3 Bln Cash And Stock

Cognizant Technology Solutions Corp. (CTSH) announced Monday it has signed a definitive agreement to acquire Belcan, LLC, a portfolio company of AE Industrial Partners and a supplier of Engineering Research & Development (ER&D) services, at a purchase price of approximately $1.3 billion in cash and stock, subject to customary adjustments. Belcan provides mission-critical digital engineering...

Read More

Indonesia Shares May Extend Winning Streak

The Indonesia stock market has moved higher in back-to-back sessions, collecting almost 130 points or 1.9 percent along the way. The Jakarta Composite Index now sits just beneath the 7,100-point plateau and it may add to its winnings on Wednesday. The global forecast for the Asian markets suggests mild upside on easing treasury yields. The...

Read More

Australia GDP Adds 0.1% In Q1

Australia\'s gross domestic product expanded a seasonally adjusted 0.1 percent on quarter in the first quarter of 2024, the Australian Bureau of Statistics said on Wednesday. That was shy of expectations for an increase of 0.2 percent following the upwardly revised 0.3 percent gain in the previous quarter (originally 0.2 percent). On an annualized basis,...

Read More

Yen Falls As European Shares Gain

The Japanese yen weakened against other major currencies in the European session on Wednesday, as investors looked ahead to Thursday\'s ECB meeting and the release of U.S. labor market data on Friday for directional cues. The European Central Bank is expected to ease borrowing costs by 25 basis points from the present record levels of...

Read More

I-Mab Inks Partnership With Bristol Myers Squibb To Evaluate Givastomig In Combination Study

Biotech company I-Mab (IMAB) announced Wednesday that it has entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb (BMY). The collaboration will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody jointly developed by I-Mab and ABL Bio, with Bristol Myers Squibb\'s immune checkpoint inhibitor, nivolumab, and...

Read More